PMID- 34094913
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210608
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of 
      Advanced Non Small Cell Lung Cancer.
PG  - 632256
LID - 10.3389/fonc.2021.632256 [doi]
LID - 632256
AB  - In the last few years the advent of targeted therapies against oncogenic drivers 
      significantly improved the survival of non small cell lung cancer (NSCLC) 
      patients with a favourable toxicity profile. Therefore, genetic testing, 
      including at least EGFR mutations and ALK/ROS1 rearrangements, should be 
      performed in all NSCLC patients (in particular with adenocarcinoma) who received 
      a diagnosis of advanced disease. This review focuses on novel druggable oncogenic 
      drivers, such as MET exon 14 mutations/MET amplification, RET fusions, BRAF V600E 
      mutations, KRAS G12C mutations, NTRK rearrangements, and HER2 alterations.
CI  - Copyright (c) 2021 Tartarone, Lapadula, Di Micco, Rossi, Ottanelli, Marini, 
      Giorgione, Ferrari, Catalano, Voltolini, Mini and Roviello.
FAU - Tartarone, Alfredo
AU  - Tartarone A
AD  - Department of Onco-Hematology, Division of Medical Oncology IRCCS-CROB Referral 
      Cancer Center of Basilicata, Rionero in Vulture, Italy.
FAU - Lapadula, Vittoria
AU  - Lapadula V
AD  - Department of Onco-Hematology, Division of Medical Oncology IRCCS-CROB Referral 
      Cancer Center of Basilicata, Rionero in Vulture, Italy.
FAU - Di Micco, Concetta
AU  - Di Micco C
AD  - Division of Medical Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni 
      Rotondo, Italy.
FAU - Rossi, Gemma
AU  - Rossi G
AD  - School of Human Health Sciences, University of Florence, Florence, Italy.
FAU - Ottanelli, Carlotta
AU  - Ottanelli C
AD  - School of Human Health Sciences, University of Florence, Florence, Italy.
FAU - Marini, Andrea
AU  - Marini A
AD  - School of Human Health Sciences, University of Florence, Florence, Italy.
FAU - Giorgione, Roberta
AU  - Giorgione R
AD  - School of Human Health Sciences, University of Florence, Florence, Italy.
FAU - Ferrari, Katia
AU  - Ferrari K
AD  - Respiratory Medicine, Careggi University Hospital, Florence, Italy.
FAU - Catalano, Martina
AU  - Catalano M
AD  - School of Human Health Sciences, University of Florence, Florence, Italy.
FAU - Voltolini, Luca
AU  - Voltolini L
AD  - Thoracic Surgery Unit, Careggi University Hospital, Florence, Italy.
FAU - Mini, Enrico
AU  - Mini E
AD  - Department of Health Sciences, Section of Clinical Pharmacology and Oncology, 
      University of Florence, Florence, Italy.
FAU - Roviello, Giandomenico
AU  - Roviello G
AD  - Department of Health Sciences, Section of Clinical Pharmacology and Oncology, 
      University of Florence, Florence, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210521
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8176852
OTO - NOTNLM
OT  - MET
OT  - genetic testing
OT  - non small cell lung cancer
OT  - oncogenic drivers
OT  - targeted therapies
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/06/08 06:00
MHDA- 2021/06/08 06:01
PMCR- 2021/01/01
CRDT- 2021/06/07 06:03
PHST- 2020/11/22 00:00 [received]
PHST- 2021/04/20 00:00 [accepted]
PHST- 2021/06/07 06:03 [entrez]
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/06/08 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.632256 [doi]
PST - epublish
SO  - Front Oncol. 2021 May 21;11:632256. doi: 10.3389/fonc.2021.632256. eCollection 
      2021.